ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a sell rating to a hold rating in a report published on Friday, March 1st.
Several other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Insys Therapeutics from a hold rating to a sell rating in a report on Saturday, November 10th. Cantor Fitzgerald initiated coverage on shares of Insys Therapeutics in a research report on Tuesday, January 22nd. They set an overweight rating and a $4.40 target price on the stock. Finally, Janney Montgomery Scott set a $11.00 price target on shares of Insys Therapeutics and gave the company a buy rating in a research report on Saturday, January 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $7.28.
Shares of INSY stock traded up $0.02 during trading hours on Friday, hitting $4.14. 1,045,299 shares of the company were exchanged, compared to its average volume of 1,165,514. Insys Therapeutics has a one year low of $3.35 and a one year high of $11.65. The stock has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.98 and a beta of 2.56.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Insys Therapeutics had a negative return on equity of 431.71% and a negative net margin of 151.79%. The company had revenue of $16.36 million for the quarter, compared to the consensus estimate of $17.93 million. On average, equities research analysts expect that Insys Therapeutics will post -1.55 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Quantamental Technologies LLC acquired a new position in Insys Therapeutics during the fourth quarter worth $26,000. Magnus Financial Group LLC acquired a new position in Insys Therapeutics during the fourth quarter worth $47,000. Two Sigma Advisers LP acquired a new position in Insys Therapeutics during the fourth quarter worth $53,000. Bank of America Corp DE boosted its holdings in Insys Therapeutics by 25.2% during the fourth quarter. Bank of America Corp DE now owns 32,129 shares of the specialty pharmaceutical company’s stock worth $112,000 after purchasing an additional 6,462 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Insys Therapeutics during the third quarter worth $113,000. 15.17% of the stock is owned by institutional investors.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
See Also: What is a Market Correction?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Insys Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.